Prevention and Treatment of COVID-19 - Dr. Peter McCullough, MD, MPH

It is becoming clear that randomized trials of single drugs will fail due to the complex and multifaceted nature of COVID-19 illness including viral-mediated organ damage, cytokine storm, and thrombosis. Additionally, most patients whether previously vaccinated or not, endure long untreated periods of two weeks or more before succumbing to hospitalization for late treatment. Thus, the administration of multiple drugs early is prudent as the next direction in randomized trials and advanced practice.

Early therapy should include:

1) monoclonal antibodies or combination antiviral therapy,

2) corticosteroids,

3) antiplatelet agents/antithrombotics,

4) supportive care including supplemental oxygen, monitoring, and telemedicine.

Randomized trials are not delivering results quickly enough to impact the pandemic, thus as an emergency medical response to acutely ill patients, we must immediately institute combination therapy and a pivot to a research strategy where several drugs are used in sequenced combination.

Future clinical trial results reported months to years will undoubtedly confirm and refine combination therapy, however, the current rates of hospitalization and death are unacceptably high under the present paradigm of watchful waiting and late hospitalization and death.

https://www.americaoutloud.com/the-mccullough-report/

See this and many more amazing videos at: https://healthfreedomsummit.com/

-------

https://gab.com/StoneTurner
https://gettr.com/user/stoneturner
https://parler.com/user/StoneTurner/
https://mewe.com/i/stoneturner/
https://twitter.com/TheStoneTurner/
https://rumble.com/user/StoneTurner/
https://bitchute.com/StoneTurner/